How strong was Stryker's growth in 2023?

Stryker grew net sales 11.1% reported and 11.5% organically for the full year to $20.5 billion. Growth was driven mostly by unit volume, with price contributing about 0.6%, and both the MedSurg and Neurotechnology and Orthopaedics and Spine segments grew at double-digit organic rates.

Why is reported EPS so much lower than adjusted EPS?

Reported full-year diluted EPS of $8.25 is below adjusted EPS of $10.60 because GAAP results include amortization of purchased intangible assets ($1.31 per share), structural optimization and special charges ($0.42), regulatory and legal matters ($0.16), medical device regulation costs ($0.19), and other items, partly offset by a $0.11 tax benefit.

What does Stryker expect for 2024?

Management expects 7.5%–9.0% organic net sales growth and adjusted diluted EPS of $11.70–$12.00, which would represent roughly 10%–13% growth over 2023's $10.60. Pricing is expected to be roughly flat, and currency is expected to be a modest headwind to sales and a $0.05–$0.10 headwind to EPS.

Is Stryker's balance sheet and cash generation improving?

Yes. Operating cash flow increased to $3.68 billion from $2.62 billion, and long-term debt declined to $10.9 billion from $11.9 billion, while shareholders' equity rose to $18.6 billion. Dividends paid were $1.14 billion, and capital spending was $575 million.

What risks should investors monitor?

Key risks include pricing pressure and cost-containment measures, FX volatility, supply chain disruptions, changes in reimbursement, product liability and recall-related costs, regulatory and legal proceedings, EU medical device regulation compliance costs, and integration of acquisitions. The rise in inventories to $4.84 billion is also worth monitoring relative to sales growth.

SYK 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed January 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Stryker closed 2023 with strong top-line momentum and solid profitability.

Fourth-quarter net sales rose 11.8% to $5.8 billion^a (11.4% organic), and full-year net sales reached $20.5 billion, up 11.1% reported and 11.5% organic, crossing the $20 billion milestone. Growth was broad-based: MedSurg and Neurotechnology grew 11.8% organically for the year and Orthopaedics and Spine grew 11.1%, with volume driving most of the increase and price contributing roughly 0.6% to 0.7%. Reported full-year diluted EPS rose 33.7% to $8.25, while adjusted EPS grew 13.5% to $10.60.

Adjusted operating margin expanded 40 bps to 24.2%, and the reported gap versus adjusted results mainly reflects amortization of purchased intangibles, structural optimization charges, and regulatory and legal items. Management guided 2024 organic net sales growth of 7.5% to 9.0% and adjusted diluted EPS of $11.70 to $12.00^b, implying roughly 10% to 13% adjusted EPS growth. Pricing is expected to be roughly flat for the full year, and unfavorable foreign exchange is expected to modestly reduce sales and reduce EPS by about $0.05 to $0.10, with the sales impact weighted toward the first half.

The guidance reflects management's view of strong procedure volumes, healthy capital demand, and a stabilizing macro environment, though the company flags risks including pricing pressure, supply chain disruption, regulatory actions, product liability, recall costs, and cyber threats. Cash flow strengthened meaningfully, with operating cash flow of $3.68 billion^c versus $2.62 billion in 2022 and capital expenditures of $575 million. Inventories rose to $4.84 billion from $4.0 billion, a build that merits monitoring against sales growth.

Long-term debt declined to $10.9 billion^d from $11.9 billion, and shareholders' equity increased to $18.6 billion. Note that this filing is the earnings press release furnished under Item 2.02 and is not a full financial statement filing; the figures are unaudited.

02—Key points

Key Highlights

Full-year 2023 net sales rose 11.1% reported (11.5% organic) to $20.5 billion, surpassing $20 billion for the first time.
Q4 2023 net sales grew 11.8% to $5.8 billion, with 11.4% organic growth driven mainly by unit volume (10.7%).
Full-year reported diluted EPS increased 33.7% to $8.25; adjusted diluted EPS rose 13.5% to $10.60.
Adjusted operating margin expanded 40 bps to 24.2% for the full year, and adjusted gross margin was 63.9%.
2024 guidance calls for 7.5%–9.0% organic sales growth and adjusted diluted EPS of $11.70–$12.00, with FX a $0.05–$0.10 headwind.
Operating cash flow rose to $3.68 billion from $2.62 billion, while long-term debt fell to $10.9 billion from $11.9 billion.
Inventories increased to $4.84 billion from $4.00 billion, a build investors should watch relative to sales growth.

03—Questions

Frequently Asked Questions

How strong was Stryker's growth in 2023?
Stryker grew net sales 11.1% reported and 11.5% organically for the full year to $20.5 billion. Growth was driven mostly by unit volume, with price contributing about 0.6%, and both the MedSurg and Neurotechnology and Orthopaedics and Spine segments grew at double-digit organic rates.
Why is reported EPS so much lower than adjusted EPS?
Reported full-year diluted EPS of $8.25 is below adjusted EPS of $10.60 because GAAP results include amortization of purchased intangible assets ($1.31 per share), structural optimization and special charges ($0.42), regulatory and legal matters ($0.16), medical device regulation costs ($0.19), and other items, partly offset by a $0.11 tax benefit.
What does Stryker expect for 2024?
Management expects 7.5%–9.0% organic net sales growth and adjusted diluted EPS of $11.70–$12.00, which would represent roughly 10%–13% growth over 2023's $10.60. Pricing is expected to be roughly flat, and currency is expected to be a modest headwind to sales and a $0.05–$0.10 headwind to EPS.
Is Stryker's balance sheet and cash generation improving?
Yes. Operating cash flow increased to $3.68 billion from $2.62 billion, and long-term debt declined to $10.9 billion from $11.9 billion, while shareholders' equity rose to $18.6 billion. Dividends paid were $1.14 billion, and capital spending was $575 million.
What risks should investors monitor?
Key risks include pricing pressure and cost-containment measures, FX volatility, supply chain disruptions, changes in reimbursement, product liability and recall-related costs, regulatory and legal proceedings, EU medical device regulation compliance costs, and integration of acquisitions. The rise in inventories to $4.84 billion is also worth monitoring relative to sales growth.

04—Continue

← View all 8-K filings